How does tofacitinib (Xeljanz) compare with upadacitinib for the treatment of peripheral spondyloarthritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Comparison of Tofacitinib vs Upadacitinib for Peripheral Spondyloarthritis

For peripheral spondyloarthritis (including psoriatic arthritis), upadacitinib demonstrates superior efficacy compared to tofacitinib, though both remain inferior to TNF inhibitors and IL-17 inhibitors as first-line biologic options.

Evidence-Based Treatment Hierarchy

Current Guideline Positioning

The 2019 ACR/SAA/SPARTAN guidelines establish a clear treatment hierarchy for peripheral spondyloarthritis 1:

  1. TNF inhibitors remain the preferred first-line biologic after NSAID failure (strong recommendation, high evidence)
  2. IL-17 inhibitors (secukinumab/ixekizumab) are conditionally recommended over JAK inhibitors (very low evidence) 1
  3. Both tofacitinib and JAK inhibitors are conditionally recommended only when TNFi are not available or after biologic failure 1

Direct Comparison: Upadacitinib vs Tofacitinib

Upadacitinib shows better clinical outcomes:

The 2021 EULAR consensus on JAK inhibitors provides critical comparative data 2:

  • For psoriatic arthritis: Upadacitinib completed two successful phase 3 trials showing efficacy for main PsA outcomes, with non-inferiority at 15 mg and superiority at 30 mg compared to adalimumab for ACR20 response 2
  • Tofacitinib (5 mg twice daily) demonstrated efficacy in PsA but lacks head-to-head superiority data against TNFi 2

For ankylosing spondylitis (axial component often present in peripheral SpA) 2:

  • Upadacitinib 15 mg daily: 52% achieved ASAS40 response at week 14 vs 26% placebo, with response evident by week 2 2
  • Tofacitinib 5 mg twice daily: Highest ASAS20 response observed, but separation from placebo took 4-8 weeks (slower onset) 2

Recent real-world data 3 shows comparable treatment persistence between the two agents (UPA: 86%/68%/54% at 6/12/18 months vs TOFA: 78%/60%/60%), though this was not statistically significant.

Clinical Decision Algorithm

When to Use Each Agent

Choose Upadacitinib over Tofacitinib when:

  • Faster disease control is needed (onset by week 2 vs 4-8 weeks)
  • Patient has failed TNFi and requires second-line JAK inhibitor
  • Both axial and peripheral manifestations are present
  • Patient is on later treatment lines (though both show reduced persistence)

Tofacitinib may be considered when:

  • Upadacitinib is unavailable or contraindicated
  • Cost considerations favor tofacitinib
  • Patient has prominent peripheral arthritis only (not axial disease)

Critical Safety Considerations

Both agents carry identical class-wide JAK inhibitor warnings 2, 4:

The 2024 EULAR PsA guidelines emphasize that JAK inhibitors should generally be used after bDMARD failure due to safety concerns 4:

  • Age ≥65 years with cardiovascular risk factors: Use only if no alternative exists
  • Active smoking or cardiovascular risk factors: Increased risk of major adverse cardiovascular events (MACE)
  • History of malignancy or venous thromboembolism: Avoid or use with extreme caution
  • Herpes zoster risk: Higher with all JAK inhibitors compared to bDMARDs

Specific to upadacitinib 5:

  • Dose-dependent effects: 15 mg shows better risk-benefit than 30 mg
  • CYP3A4 interactions: Requires dose adjustment with strong inhibitors (ketoconazole increases exposure 1.75-fold) or inducers (rifampin decreases exposure to 0.39-fold)

Practical Treatment Positioning

The 2024 EULAR PsA recommendations explicitly state 4:

  • JAK inhibitors are second-line targeted therapies (or third-line DMARDs overall)
  • Use "when a bDMARD is not appropriate" - meaning contraindications, practical barriers to injections, or strong patient preference for oral therapy
  • Patients must weigh preferences against potential cardiovascular and malignancy risks

Common Pitfalls to Avoid

  1. Do not use JAK inhibitors as first-line biologics - TNFi and IL-17i have superior evidence and safety profiles 1, 4
  2. Do not ignore cardiovascular risk stratification - The ORAL Surveillance trial data (tofacitinib in RA) applies to all JAK inhibitors in all indications 4
  3. Do not combine with other immunosuppressants unnecessarily - Concomitant csDMARD use increases discontinuation risk 3
  4. Do not assume equivalence to biologics - Guidelines conditionally recommend IL-17i over JAK inhibitors 1

When Neither Agent is Appropriate

Strongly prefer TNF inhibitors or IL-17 inhibitors when:

  • Patient is biologic-naïve after NSAID failure
  • Age >65 with any cardiovascular risk factors
  • History of thromboembolism or malignancy within 5 years
  • Active smoking status
  • Pregnancy planning (both sexes - filgotinib affects spermatogenesis, extrapolate caution to class) 2

Bottom line: While upadacitinib shows marginally better efficacy than tofacitinib for peripheral spondyloarthritis, both remain inferior to TNF and IL-17 inhibitors and should be reserved for patients who have failed or cannot use biologics, with careful cardiovascular and malignancy risk assessment mandatory before initiation 1, 2, 4.

References

Related Questions

For a patient currently receiving adalimumab (Humira), which is the preferred switch: upadacitinib (Rinvoq) 15 mg orally once daily or tofacitinib (Xeljanz) 5 mg twice daily?
In a patient with moderate-to-severe rheumatoid arthritis inadequately controlled by conventional disease-modifying antirheumatic drugs, when should upadacitinib be preferred over tofacitinib, and vice versa?
For a patient with rheumatoid arthritis, is there a less expensive JAK inhibitor that provides comparable efficacy to upadacitinib?
What are the FDA‑approved indications for tofacitinib in adult patients?
How is the risk of kidney transplant rejection assessed?
What is the recommended evaluation and management for seminal vasculitis in a male patient presenting with scrotal or pelvic pain, ejaculatory discomfort, and possible infertility?
How is malignant hyperthermia identified in patients receiving volatile anesthetics or succinylcholine?
Should polymyxin B be preferred over colistin for lung infections caused by multidrug‑resistant Gram‑negative bacteria, especially in patients with impaired renal function, and what are the recommended dosing regimens?
What is the recommended intravenous fluconazole dose, frequency, dilution, and treatment duration for a symptomatic Candida urinary tract infection?
In a critically ill intubated adult with multidrug‑resistant Gram‑negative pneumonia, how does lung penetration of colistin compare to polymyxin B?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.